Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Medtronic
Baxter
Express Scripts
Mallinckrodt
Colorcon
Boehringer Ingelheim

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

RESCRIPTOR Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Rescriptor, and when can generic versions of Rescriptor launch?

Rescriptor is a drug marketed by Viiv Hlthcare and is included in one NDA. There is one patent protecting this drug.

This drug has twenty-five patent family members in twenty countries.

The generic ingredient in RESCRIPTOR is delavirdine mesylate. One supplier is listed for this compound. Additional details are available on the delavirdine mesylate profile page.

Drug patent expirations by year for RESCRIPTOR
Drug Prices for RESCRIPTOR

See drug prices for RESCRIPTOR

Recent Clinical Trials for RESCRIPTOR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of California, San DiegoPhase 2/Phase 3
National Institute of Mental Health (NIMH)Phase 2/Phase 3
National Institutes of Health (NIH)Phase 2/Phase 3

See all RESCRIPTOR clinical trials

Synonyms for RESCRIPTOR
(1-(5-METHANSULPHONAMIDO-1H-INDOL-2-YL-CARBONYL)4-[METHYLAMINO)PYRIDINYL]PIPERAZINE
(N-[2-[4-[3-(1-methylethylamino)pyridin-2-yl]piperazin-1-yl]carbonyl-1H-indol-5-yl] methanesulfonamide)
1-(3-((1-Methylethyl)amino)-2-pyridinyl)-4-((5-((methylsulfonyl)amino)-1H-indol-2-yl)carbonyl)piperazine
136817-59-9
147221-93-0 (mesylate)
2-(4-(5-Methanesulfonamido-1H-indol-2-ylcarbonyl)-1-piperazinyl)-N-(1-methylethyl)-3-pyridinamine
AB01275468-01
AC1L1KRN
AKOS015965076
AN-566
API0000513
AX8123689
BC219340
BCP08068
BDBM1944
BHAP der
BHAP-U 90152
C-22553
C06941
C22H28N6O3S
CAS-136817-59-9
CC-26317
CHEBI:119573
CHEMBL593
CS-1660
CTK8E7248
D07782
DB00705
Delavirdin
Delavirdina
Delavirdine
Delavirdine (*Mesylate salt*)
Delavirdine (INN)
Delavirdine [INN]
Delavirdine(U-90152) & .a.IFN
Delavirdinum
DLV
DOL5F9JD3E
DSSTox_CID_2892
DSSTox_GSID_22892
DSSTox_RID_76776
DTXSID6022892
FT-0603115
HMS2089F20
HMS3713A14
HY-10571
J-006916
KB-49645
KB-78327
LS-172972
MET046
Methanesulfonamide, N-[2-[[4-[3-[(1-methylethyl)amino]-2-pyridinyl]-1-piperazinyl]carbonyl]-1H-indol-5-yl]-
Methanesulfonamide,N-[2-[[4-[3-[(1-methylethyl)amino]-2-pyridinyl]-1-piperazinyl]carbonyl]-1H-indol-5-yl]-
MolPort-003-846-188
N-(2-(1-(3-(isopropylamino)pyridin-2-yl)piperazine-4-carbonyl)-1H-indol-5-yl)methanesulfonamide
N-(2-(4-(3-(Isopropylamino)pyridin-2-yl)piperazine-1-carbonyl)-1H-indol-5-yl)methanesulfonamide
N-(2-{4-[3-(isopropylamino)pyridin-2-yl]piperazine-1-carbonyl}-1H-indol-5-yl)methanesulfonamide
N-[2-({4-[3-(propan-2-ylamino)pyridin-2-yl]piperazin-1-yl}carbonyl)-1H-indol-5-yl]methanesulfonamide
N-[2-(4-{3-[(propan-2-yl)amino]pyridin-2-yl}piperazine-1-carbonyl)-1H-indol-5-yl]methanesulfonamide
N-[2-[4-[3-(isopropylamino)-2-pyridyl]piperazine-1-carbonyl]-1H-indol-5-yl]methanesulfonamide
N-[2-[4-[3-(propan-2-ylamino)pyridin-2-yl]piperazine-1-carbonyl]-1H-indol-5-yl]methanesulfonamide
N-{2-[(4-{3-[(1-methylethyl)amino]pyridin-2-yl}piperazin-1-yl)carbonyl]-1H-indol-5-yl}methanesulfonamide
N-{2-[(4-{3-[(propan-2-yl)amino]pyridin-2-yl}piperazin-1-yl)carbonyl]-1H-indol-5-yl}methanesulfonamide
N-{2-[4-(3-Isopropylamino-pyridin-2-yl)-piperazine-1-carbonyl]-1H-indol-5-yl}-methanesulfonamide
NCGC00168776-01
NCGC00168776-02
NCGC00168776-03
Piperazine, 1-[3-[(1-methylethyl)amino]-2-pyridinyl]-4-[[5-[(methylsulfonyl)amino]-1H-indol-2-yl]carbonyl]- & alpha-Interferon
PNU-90152-T
Rescriptor (TM)
RT-012247
SC-82579
SCHEMBL34420
SPP
SR-05000001471
SR-05000001471-1
Tox21_112637
Tox21_112637_1
U 90152
U 90152; Rescriptor
u-90152
U90152S (*Mesylate salt*)
UNII-DOL5F9JD3E
ZINC18516586

US Patents and Regulatory Information for RESCRIPTOR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Viiv Hlthcare RESCRIPTOR delavirdine mesylate TABLET;ORAL 020705-001 Apr 4, 1997 DISCN Yes No   Start Trial   Start Trial   Start Trial
Viiv Hlthcare RESCRIPTOR delavirdine mesylate TABLET;ORAL 020705-002 Jul 14, 1999 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for RESCRIPTOR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Viiv Hlthcare RESCRIPTOR delavirdine mesylate TABLET;ORAL 020705-001 Apr 4, 1997   Start Trial   Start Trial
Viiv Hlthcare RESCRIPTOR delavirdine mesylate TABLET;ORAL 020705-002 Jul 14, 1999   Start Trial   Start Trial
Viiv Hlthcare RESCRIPTOR delavirdine mesylate TABLET;ORAL 020705-001 Apr 4, 1997   Start Trial   Start Trial
Viiv Hlthcare RESCRIPTOR delavirdine mesylate TABLET;ORAL 020705-002 Jul 14, 1999   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
McKesson
Baxter
AstraZeneca
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.